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Summary: We evaluated a homogenous immunoturbidimetric assay for haemoglobin Alc (Tina-quant® Haemoglo-
bin Alc, Boehringer Mannheim, GmbH, Mannheim, Germany) adapted to a Cobas® Mira S analyser (F. Hoffmann-
La Roche & Co., Basel, Switzerland) and not requiring sample pretreatment. Between-day CV's determined over a
6 week period were 5.9% and 5.3% for mean haemoglobin Alc values of 5.4% and 17.0% of total haemoglobin
respectively. The imprecision was higher than with an in-house ion-exchange high performance liquid Chromato-
graphie method. Bilirubin, triacylglycerols and the labile fraction of haemoglobin Aj c did not interfere with the
assay of haemoglobin AJc. Fetal haemoglobin is not recognized by the antibodies used. Results correlated well with
those obtained by high performance liquid chromatography. In conclusion, the Tina-quant® assay is not prone to
common interferences and allows the rapid and automated determination of haemoglobin A lc on open photomet-
ric analysers.
Introduction
Glycohaemoglobin measurement is widely used to mon-
itor glycaemic control in diabetic patients (1—4). Gly-
cated haemoglobin comprises a variety of molecular
species formed by non-enzymatic glycation of haemo-
globin (Hb) components at various sites. The reaction of
glucose with the N-terminal amino-group of the haemo-
globin -chain generates haemoglobin Alc (HbA]c); the
latter fraction is best correlated with the average blood
glucose concentration (1).
Haemoglobin Alc values provide a time-integrated retro-
spective view on circulating glucose levels over a 4—6
week period. Repeated determinations of HbAlc in dia-
betic patients help to assess the compliance with therapy
and the risk to develop the devastating chronic compli-
cations of the disease (1). Many widely used methods
for quantitation of HbAlc, such as ion-exchange micro-
column methods, high performance liquid chromatogra-
phy (HPLC) and electrophoretic techniques, exploit the
charge differences between glycated and non-glycated
Hb. Boronate affinity chromatography is based on the
structural characteristics of the carbohydrate moiety (1).
HPLC-methods measure HbAlc with great precision, but
are labour intensive and have a rather low throughput
(1). New automated methods have recently been devel-
oped for the fast and reliable determination of HbAlc
(5—13). In this study, we evaluated a new homogenous
immunoassay (9—11) for the determination of HbAlc
(Tina-quant® Haemoglobin Alc, Boehringer Mannheim
GmbH, Mannheim, Germany) adapted to a Cobas®
MiraS analyser (Hoffmann-La Roche & Co Ltd, Basel,
Switzerland).
Materials and Methods
Blood samples
Whole-blood specimens were collected into Monovette-tubes
coated with lithium heparin anticoagulant (Sarstedt, Essen, Bel-
gium). Samples were stored at 2—8 °C and analysed within one
week after collection.
Assay procedure
Haemolysates were prepared by adding 10 μΐ of whole blood to
1 ml cyanide-free haemolysis reagent. No pretreatment for removal
of the labile fraction was performed. Total Hb and HbAlc were
measured on a Cobas® Mira S analyser operated at 37 °C, accord-
ing to the manufacturers' instructions. The test conditions are listed
in table 1. The instrument calculates the HbAic/total Hb concentra-
tion ratio and expresses HbAic results as fraction of total Hb.
Comparison method:
high performance liquid chromatography
The HPLC procedure consisted in an adaptation of the method of
Stenman et al. (14). Blood cells were sedimented by centriftigation
at 1000 g for 10 minutes at room temperature. The packed cells
were washed three times with a 9 g/1 NaCl solution. One volume
of packed washed cells was lysed by addition of one volume of
water. Delipidation was performed by mixing five volumes of ly-
sate with two volumes of carbon tetrachloride. The mixture was
centrifuged for 5 minutes at room temperature and 100 μΐ of the
clear aqueous phase was diluted with 3 ml of hydrolysis buffer (25
mmol/1 phosphate buffer pH 4.85 with 4 mmol/1 KCN). After a 3 h
incubation at 37 °C to remove the labile glycated fraction, a 20 μΐ
aliquot of the diluted haemolysate was injected onto a Mono S H R
5/5 column (Pharmacia LKB Biotechnology, AB, Uppsala, Swe-
den). The HPLC method was validated by repeated participation
in an international external quality control program (Stichting
Kwaliteitsbewaking voor Klinsch-Chemische Ziekenhuislaborato-
ria, the Netherlands).
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Tab. 1 Adaptation of Tina-quant® HbAic to Cobas® Mira S.
Conditions
Measurement mode
Calibration
— mode
- calibrators (reagent 3)
n
duplicates
units
range
Reagent blank
Wavelength (nm)
Cycle 1:
- pipetting
— reading
Cycle 2:
— pipetting
Cycle 4:
- reading
Cycle 12:
— reading
Cycle 13:
— pipetting
Cycle 30:
- reading
a
 reagent 4: 0.2 mol/1 phosphate buffer (pH 7.4)
b
 reagent 1: sheep anti HbAlc > 0.5 g/I in 0.05 mol/1
HbA lc
absorbance
Iogit/log5
5
yes .
g/i
0.0-25.1
no
340
8 μΐ sample
15 μΐ Η20
350 μΐ reagent lb
—
—
-
-
absorbance at t = 5 min
70 μΐ reagent 2C
20 μΐ Η2Ο
absorbance at t = 12.5 min
c
 reagent 2:
N-morpho-
Total Hb
absorbance
linear
1
yes
g/1
133'
yes
600
230 μΐ reagent 4a
absorbance at t =
30 μΐ sample
20 μΐ Η2Ο
absorbance at t —
—
—
—
—
haemoglobin Alc polyhapten ^ 20 mg/1
MES buffer, pH 6.2
25s
100s
in 0.05
lino-ethanesulphonic acid (MES), pH 6.2
Imprecis ion studies
Between-day imprecision was assessed by analysing erythrolysates
(stored at —70 °C and routinely used as control material for the in-
house HPLC) over a 6 week period using 5 calibrations and two
different test pack lots. The same erythrolysates were also analysed
with the HPLC method over the same period.
Lineari ty studies
Linearity was evaluated by preparing mixtures of two haemolysates
with equal total Hb concentration (130 g/1), one from a patient with
poorly controlled diabetes (14.5% HbAlc) and one from a non-
diabetic subject (4.0% HbAlc). The mixtures were analysed in du-
plicate in the same analytical run.
Interference studies
To evaluate the effect of the total Hb concentration, packed cells
were prepared from 5 ml of an anticoagulated blood sample (123
g/1 total Hb, 5.6% HbAlc) and 100 μΐ aliquots of the cell suspen-
sion were mixed with various volumes (50—400 μΐ) of the original
plasma. In this way, samples were prepared with a fixed HbAlc
fraction and a total Hb concentration varying between 66 and
200 g/1.
Interference by the labile HbAic fraction was evaluated by supple-
menting an anticoagulated whole blood sample with 50 mmol/1 D-
glucose. Haemolysates were analysed before and after 2 h and 4 h
incubation at 37 °C. The formation of the labile fraction was con-
firmed by analysing the samples with HPLC without removal of
the labile fraction, i.e. with omission of the 3 h incubation in acid
hydrolysis buffer.
Bilirubin interference was evaluated by preparing bilirubin supple-
mented samples according to the procedure of Click et al. (15).
Two different experiments were performed to evaluate the effect
of lipaemia. In the first experiment, a whole blood sample was
supplemented with Intralipid® 20% (KabiVitrum Inc., Alameda,
CA 94501) up to 1 g/1. In the second experiment, haemolysates
were supplemented with VLDL-rich plasma to test the effect of
endogenous lipids (and other endogenous compounds).
The effect of foetal haemoglobin (HbF) was checked as follows:
cord blood (70% HbF as determined by HPLC) was mixed with
adult blood (7.5% HbAlc as determined by immunoassay) in vari-
ous proportions (volume fractions of HbF = 0.2, 0.4, 0.6 and 0.8).
The total Hb concentration was 134 g/1 in both samples as deter-
mined by the Tina-quant® total Hb assay. The original samples
and the mixtures were analysed by immunoassay and the results
(expressed in %) compared with the expected values, calculated as
7.5 (1-volume fraction of cord blood).
Results
Imprecision studies
Between-day imprecision was assessed by analysing
erythrolysates over a 6 week period (n = 12) and
amounted to 6.9% and 5.3% for HbAlc values of 5.4%
and 17.0% respectively. For comparison, between-day
CV's with our in-house HPLC-method were only 1.7%
and 0.8% for the same erythrolysates analysed over the
same period (n = 12). Over a 9 month period (n = 12),
CV's with HPLC were 1.8% and 0.8%.
Linearity studies
Assay linearity was confirmed between 4.0% and 14.5%
HbAlc by analysing mixtures of samples with low and
high HbAlc content. The correlation between measured
(y) and calculated (x) values was: y = 0.99x — 0.06
(r = 0.9993; syx = 0.16%).
Interference studies
Five samples with total Hb ranging from 66 g/1 to 200
g/1, w,ere prepared by mixing packed red cells from a
Weets et al.r Evaluation of an immunoturbidimetric assay for haemoglobin AIC 451
non-diabetic subject with various volumes of the origi-
nal plasma. The fraction of HbAic as determined with
the Tina-quant® method averaged 5.5% (S.D. = 0.3%;
range = 4.9%—5.8%) and was not correlated with the
total Hb concentration (p = 0.25).
Possible interference by the labile fraction of HbAJc was
evaluated by incubation of an anticoagulated blood sam-
ple with 50 mmol/1 glucose at 37 °C. Under these condi-
tions, large amounts of labile fraction were formed as
evidenced by the HPLC measurements performed with-
out removal of the labile fraction (see methods): the ap-
parent HbAlc (i. e. HbAic plus labile fraction) rose from
6.7% before incubation to 16.2% and 23.4% after 2 h
and 4 h of incubation respectively. In contrast, HbAJc
determined by immunoassay ranged between 5.1 and
5.7%, reflecting method imprecision rather than interfer-
ence by the labile fraction.
Bilirubin up to 350 μιηοΐ/l (20 mg/dl) did not change
the results of the immunoassay by more than 0.5% at a
levelof6.1%HbAlc.
An important negative interference was observed in In-
tralipid® supplemented samples. Haemoglobin A lc val-
ues were 6.2%, 4.8%, 4.4%, 4.0% and 3.5% for samples
supplemented with Intralipid® equivalent to final triacyl-
glycerols concentrations of 0.0 g/1, 0.25 g/1, 0.50 g/1,
0.75 g/1 and 1.0 g/1 respectively. Very low density lipo-
proteins (VLDL) and other endogenous compounds,
however, did not interfere in the immunosassay as as-
sessed by supplementing erythrolysates with VLDL-rich
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Fig. 1 Correlation of HbAlc results obtained with the Tina-
quant® immunoassay with results obtained by HPLC for 85 adult
patients without genetic Hb variants.
Regression line by linear regression analysis: y = 1.37x - 3.72;
r = 0.96; Syx = 0.93%. The slope was significantly different from
1 (95% confidence interval = 1.29-1.46) and the intercept was
significantly different from 0 [95% confidence interval
= (-4.50)- (-2.94)].
plasma. Haemoglobin A lc averaged 9.9% (S.D.
= 0.5%; range 8.9-10.4%) in haemolysates prepared
from washed reticulocytes and spiked with different vol-
umes of VLDL-rich plasma (n = 6; up to 50 μΐ plasma
per ml haemolysate). The correlation between HbAic
values and the added plasma volume was not statistic-
ally significant (p = 0.15).
Haemoglobin Alc was not detected (< 0.5%) in cord
blood samples, indicating that HbF, whether glycated or
acetylated, is not recognized by the antibodies used in
the Tina-quant® immunoassay. Foetal haemoglobin also
did not affect the measurement of HbAlc, as judged by
the linear relation between measured (y) and expected
(x) values for the mixtures of cord blood and adult blood
(y = 0.75 + 0.92x; r = 0.995).
Method comparison
Haemoglobin Alc values obtained with the immuno-
assay correlated well with those obtained by the HPLC
method, albeit with a significant slope and intercept ef-
fect (fig. 1). With the exception of two samples (one
with 40% HbC and one with 35% HbS), all samples
containing increased amounts of variant Hb (2—20%
HbF, 22-37% HbS, 39% HbC and 37% HbD) closely
followed the correlation for HbA containing samples
(fig. 2).
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Fig. 2 Correlation of HbAic results obtained with the Tina-
quant® immunoassay with results obtained by HPLC for 11
patients with significant amounts of variant Hb [HbS (Δ, A); HbC
(D, Π); HbD (o); HbF (x)].
HbXlc represents the sum of % HbAlc and % HbClc, HbSlc or
HbDic; HbCic is measured; HbSlc is computed according to the
formula: % HbSlc = % HbS χ (% ΗοΑ1(/% Hb'A); HbDlc was
calculated similarly, taking into account the % HbD instead of the
% HbS.
The solid line represents the regression line from figure 1; with the
exception of two samples (D with 40% HbC and A with 35% HbS)
all samples containing increased amounts of variant Hb followed
the correlation for samples containing almost exclusively HbA.
452 Weets et al.: Evaluation of an imrnunoturbidimetrie assay for haemoglobin Alc
Discussion
The present imniunoturbidimetric assay allows the fast
and automated determination of HbAlc on open photo-
metric analysers (9-11). In contrast to the more labour-
intensive HPLC method, this assay requires no extensive
pretreatment of the sample prior to analysis. Although
the Tina-quant® immunoassay is less precise than the
in-house HPLC method, its imprecision is similar to that
observed with other immunoassays or automated affinity
binding assays (5-13). Hamwi et al. (11) and Lyon et
al. (10) reported slightly lower between-day CV's, be-
tween 2.4 and 5.9%, determined however over a shorter
period (11 days, n = 11 and 10 days, n = 10 respec-
tively) and using one calibration. The CV's obtained
using immunoassays (7, 9—13) often exceed the desired
maximum imprecision of 3% for HbAlc (16, 17). The
imprecision might be improved by performing duplicate
measurements.
The results of the immunoassay were not affected by
common interferences like bilirubin, VLDL-rich plasma
and labile HbAlc. The labile fraction of glycohaemo-
globin reflects the prevalent blood glucose concentra-
tion. Failure to efficiently remove this labile fraction
prior to the assay causes an apparent increase in % gly-
cohaemoglobin with most methods based on charge sep-
aration. Consequently, labile HbAlc does interfere with
the HbAlc measurement of HPLC, thus requiring sample
pretreatment. The effect of the labile fraction on the
Tina-quant® immunoassay was evaluated by in vitro in-
cubation of whole blood specimens supplemented with
D-glucose (50 mmol/1 final). No significant increase of
the HbAlc values was observed with the immunoassay
which indicates that the assay is insensitive to consider-
able amounts of labile fraction. Therefore, there is no
need to remove the labile fraction prior to the Tina-
quant® assay.
The alleged specificity of the antibodies for the glucose
moiety of the ß-chain N-terrninus suggests that the dif-
ferent HbXlc's investigated should be equally recog-
nized (see package insert). The present study, however,
did not allow us to draw any conclusion about the effect
of variant Hb's, since some variant containing samples
followed the overall correlation with HPLC whereas in
others the immunoassay overestimated the apparent
HbAic content compared to HPLC. further studies are
thus required to confirm the antibodies' specificity.
Overall, the results of the immunoassay correlated fairly
well with the HPLC method in spite of having a slope
of 1.37 with an intercept of —3.72. Haemoglobin Alc
values less than 8% were lower with the immunoassay
in comparison with HPLC and values above 10% were
higher with the immunoassay. Hamwi et al. (11) using
the Tina-quant® assay and John et al. (7) using the Dako
enzyme-immunoassay noted a similar bias between
immunoassays and HPLC, especially at low HbAlc val-
ues. This bias could be a consequence of the higher
specificity of the immunoassay for N-terminal glycation
as compared to HPLC. Differences in calibration pro-
cedures may also contribute to the observed bias (18,
19). In our HPLC assay, HbAlc is determined by ex-
pressing the HbAlc peak area as fraction of the total
peak area. No calibration was performed. Results ob-
tained by the immunoassay, on the contrary, depend
heavily on the calibrator-assigned values. Standardiza-
tion of the HbAjc measurements by use of common cali-
brators is essential to improve interlaboratory and be^
tween-method consistency (18, 19).
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